POLYMORPHYSM BETA FIBRINOGEN GENE -455 G TO A IN ISCHEMIC STROKE : ASSOCIATED WITH BARTHEL INDEX

Objective. Carrier of the A allele in the -455 locus of the beta fibrinogen promoter region, has previously been shown to be associated with elevated fibrinogen levels. The relationship between fibrinogen gene polymorphism and outcome subjects with aspirin therapy is not clear. Because it is biologically plausible that a prothrombotic polymorphism may exert a differential effect across different ages, we classified study as young and old ages. Methods. A cohort study design comprises 136 consecutive patients was done. All patients with acute ischemic stroke who were admitted to Adam Malik Hospital were divided into two groups: below and above the age of 55 years. Subjects received anti platelet aspirin for 3 months. Genomic DNA was extracted from peripheral blood lymphocyte using standard protocol. Level fibrinogen plasma, mRS scale and cerebral imaging were available. Results. Genotype distributions were 66.2% for GG, 27.2% for GA and 6.6% for AA. At a young age, genotype distributions were 30.1% (GG), 15.4% (GA) and 6.6% (AA). After administration of aspirin, plasma fibrinogen levels was 248.65(100.71) mg/dl and 235.75(82.01) mg/dl, respectively for young and old age. The cut-off value of plasma fibrinogen concentration was 268.05 mg/dl. In a logistic regression model, the -455 G/A locus genotype showed a significant interaction between age and fibrinogen level in Barthel Index (BI) day 0 (p<0.25).The identified relative risk on age was 0.67 (0.30-1.49) and fibrinogen level was 0.78 (0.37 ? 1.63). Conclusions. Plasma fibrinogen levels decreased after administration of either aspirin or polymorphisms according to age. Identification of stroke risk factors based on the relative risk of plasma fibrinogen levels are high degree in young age.